摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(1-methyl-1H-indazol-5-ylamino)-9-cyclopentyl-8,9-dihydro-5,7,7-trimethyl-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one | 946823-75-2

中文名称
——
中文别名
——
英文名称
2-(1-methyl-1H-indazol-5-ylamino)-9-cyclopentyl-8,9-dihydro-5,7,7-trimethyl-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one
英文别名
9-cyclopentyl-5,7,7-trimethyl-2-[(1-methylindazol-5-yl)amino]-8H-pyrimido[4,5-b][1,4]diazepin-6-one
2-(1-methyl-1H-indazol-5-ylamino)-9-cyclopentyl-8,9-dihydro-5,7,7-trimethyl-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one化学式
CAS
946823-75-2
化学式
C23H29N7O
mdl
——
分子量
419.53
InChiKey
MTBYUKCPWJAZGK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    31
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    79.2
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • Dihydrodiazepines useful as inhibitors of protein kinases
    申请人:Kay David
    公开号:US20080167289A1
    公开(公告)日:2008-07-10
    The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    本发明涉及一种作为蛋白激酶抑制剂的化合物。该发明还提供包含所述化合物的药用合适组合物,并提供使用这些组合物在治疗各种疾病、状况或障碍中的方法。该发明还提供制备本发明化合物的方法。
  • [EN] METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS<br/>[FR] PROCÉDÉS DE PRÉPARATION DE DÉRIVÉS DE PYRIMIDINE UTILES COMME INHIBITEURS DE LA PROTÉINE KINASE
    申请人:VERTEX PHARMA
    公开号:WO2011036566A1
    公开(公告)日:2011-03-31
    A method of preparing a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims, comprises the steps of: a) reacting a compound represented by Structural Formula (A) with FTNR1R7 under suitable conditions to form a compound represented by Structural Formula (B); and b) i) when R12 is -NO2, and R11 is -OR14: 1) cyclizing the compound represented by Structural Formula (B) under suitable cyclisation conditions to form a compound represented by Structural Formula (II); and 2) optionally reacting the compound represented by Structural Formula (II) with R9-LG2, wherein LG2 is a suitable leaving group, to form the compound represented by Structural Formula (I), wherein R8 is R9; or ii) when R12 is halogen, and R11 is -NHR13: 1) cyclizing the compound represented by Structural Formula (B) under suitable cyclisation conditions to form the compound represented by Structural Formula (I); and 2) optionally, when R13 is - H, reacting the compound produced from step b), ii), 1) with R9-LG2, wherein LG2 is a suitable leaving group, to form the compound represented by Structural Formula (I) wherein R8 is R9.
    一种制备化合物结构式(I)或其药学上可接受的盐的方法,其中结构式(I)中的变量如说明书和权利要求中所述,包括以下步骤:a)在适当的条件下,将化合物结构式(A)与FTNR1R7反应,形成化合物结构式(B);和b)i)当R12为-N02,而R11为-OR14时:1)在适当的环化条件下,使化合物结构式(B)环化形成化合物结构式(II);和2)可选择地将化合物结构式(II)与R9-LG2反应,其中LG2是适当的离去基团,形成化合物结构式(I),其中R8为R9;或ii)当R12为卤素,而R11为-NHR13时:1)在适当的环化条件下,使化合物结构式(B)环化形成化合物结构式(I);和2)可选择地,当R13为-H时,将从步骤b)ii)1)产生的化合物与R9-LG2反应,其中LG2是适当的离去基团,形成化合物结构式(I),其中R8为R9。
  • DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES
    申请人:Kay David
    公开号:US20100190765A1
    公开(公告)日:2010-07-29
    The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    本发明涉及一种作为蛋白激酶抑制剂有用的化合物。该发明还提供包括所述化合物的药学上可接受的组合物,并且提供使用这些组合物治疗各种疾病、状况或障碍的方法。该发明还提供制备本发明化合物的方法。
  • METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS
    申请人:Charrier Jean-Damien
    公开号:US20120271045A1
    公开(公告)日:2012-10-25
    A method of preparing a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims. Additionally, the present invention relates to compounds of Structural Formula (I), which are useful as inhibitors of protein kinase.
    一种制备结构式(I)所代表的化合物或其药学上可接受的盐的方法,其中结构式(I)的变量如规范和权利要求所述。此外,本发明涉及结构式(I)的化合物,其作为蛋白激酶抑制剂是有用的。
  • US7622463B2
    申请人:——
    公开号:US7622463B2
    公开(公告)日:2009-11-24
查看更多

同类化合物

阿昔替酯 螺喹唑啉 苯并[g][1,2,3]三唑并[4',5':5,6]吡啶并[2,1-b]喹唑啉-13(2H)-酮 脱氢利培酮 盐酸曲林菌素 甲硫利马唑 甲基8-乙基-2-甲氧基-5-氧代-5,8-二氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基8-乙基-2-(甲硫基)-5-氧代-5,6,7,8-四氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基2-乙氧基-8-乙基-5-氧代-吡啶并[6,5-d]嘧啶-6-羧酸酯 溴他替尼 泮托拉唑杂质DF 氨甲酸,[(2R,3E)-2-羟基-3-戊烯基]-,1,1-二甲基乙基酯(9CI) 柱孢藻毒素 曲美替尼 曲美替尼 曲喹辛 异噻唑并[5,4-d]嘧啶,3-亚硝基-(9CI) 帕潘立酮棕榈酸酯 帕潘立酮杂质7 帕潘立酮杂质16 帕潘立酮杂质 帕潘立酮杂质 帕潘立酮去氟杂质 帕潘立酮Z-异构体 帕潘立酮 帕泊昔布杂质117 帕布昔利布杂质46 帕博西尼杂质S 帕利哌酮杂质05 帕利哌酮杂质03 帕利哌酮杂质02 帕利哌酮十四酸酯 帕利哌酮N-氧化物 布喹特林 巴马斯汀 奥卡哌酮 多夸司特 嘧啶并[4,5-d]嘧啶-2,4,5(1H,3H,6H)-三酮,7-乙氧基-1,3-二甲基-6-(苯基甲基)- 吡曲克辛 吡嘧司特钾 吡嘧司特 吡啶并[4,3-d]嘧啶-4(1H)-酮,4,5,6,7-四氢-6-甲基-2-苯基- 吡啶并[4,3-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,4-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,2-d]嘧啶-4(3H)-酮,3-甲基-2-(甲基氨基)- 吡啶并[3,2-d]嘧啶-4(3H)-酮 吡啶并[3,2-d]嘧啶-4(1H)-酮,2,3-二氢-3-(2-羟基苯基)-2-硫代- 吡啶并[3,2-d]嘧啶-2,4(1H,3H)-二酮 吡啶并[2,3-d]嘧啶-7(8h)-酮,2,6-二溴-8-环戊基-5-甲基- 吡啶并[2,3-d]嘧啶-7(8H)-酮